Repligen (RGEN) Q2 FY26 earnings call

Repligen delivered excellent Q2 FY26 results, with strong organic growth driven by Proteins and Analytics, leading to a raised full-year outlook. The company is strategically expanding its cell therapy offerings through the accretive BioLife acquisition, while also focusing on integrated solutions and product lifecycle management to capture future growth opportunities, particularly in onshoring.